论文信息 - Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. - 字舞流文

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

P. Kabos | C. Twelves | N. Turner | I. Irurzun-Arana | E. Calvo | C. Morrow | R. Baird | A. Armstrong | E. Ciruelos | T. Klinowska | J. Garcia-Corbacho | Mafalda Oliveira | C. Vaklavas | J. Lindemann | E. Hamilton | M. Patel | M. Ruiz-Borrego | Jason Incorvati | Begoña Bermejo de la Heras | Tim Brier | J. García-Corbacho